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Introduction 
Eliciting broadly neutralising antibodies against the human 
immune deficiency virus 1 (HIV-1) is still considered to be an 
inevitable goal of HIV vaccine research. Because of the variability of its 
envelope proteins the conserved domains of these proteins represent a 
good potential target for broadly neutralising antibodies. One of these 
conserved domains is the membrane proximal external region (MPER) 
of the transmembrane envelope (TM) protein gp41 of HIV-1. Two of 
the most potent broadly neutralising antibodies against HIV-1, mAb 
2F5 and mAb 4E10 bind to epitopes located in the MPER of gp41 [1,2]. 
This domain was considered to be an excellent target region for vaccine 
development [3]. However, numerous immunisation studies using 
proteins containing the epitopes of mAb 2F5 and mAb 4E10 failed to 
induce broadly neutralising antibodies so far [4,5]. 
In contrast to the situation with HIV-1, neutralising antibodies 
against different gammaretroviruses such as porcine endogenous 
retrovirus [6,7], feline leukaemia virus [8-10] and Koala retrovirus 
[11] have been easily induced by immunisation with the recombinant 
ectodomains of their TM proteins. The epitopes recognised by the 
immune sera were located in the N-terminal fusion peptide proximal 
region (FPPR) and in the C-terminal MPER of p15E. The MPER of 
PERV, FeLV and KoRV is homologous to that of gp41 of HIV-1 and 
despite the evolutionary distance between gammaretroviruses and 
HIV-1 a limited sequence homology of the epitopes was identified [6-
11] (Figure 1a).
When studying the mechanisms of neutralisation by mAb 2F5 and 
mAb 4E10, complex coherences between the structure of the MPER and 
antibody binding were observed [12-14]. Interaction of both antibodies 
with lipids, their long hydrophobic CDR3 loop and cross-reactivity 
with cardiolipin have been discussed controversially as possible reasons 
for the failure of all previous immunisation attempts [15-17]. Since 
there is evidence for intramolecular interactions between the MPER 
and the FPPR during infection and neutralisation [18-22] and a peptide 
corresponding to the sequence of the FPPR has been shown to increase 
binding of mAb 2F5 to its epitope [14], it was suggested that the FPPR 
may be required to generate a conformation which will be able to 
induce broadly neutralising antibodies of the 2F5 and 4E10. 
Enhanced binding of mAb 2F5 and mAb 4E10 to their epitopes was 
observed in a lipid environment compared with free MPER peptides 
[23-26]. These findings raise the question, whether membranes or 
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Abstract
All attempts to induce broadly neutralising antibodies such as mAb 2F5 and mAb 4E10 targeting conserved 
epitopes in the membrane proximal external region (MPER) of the transmembrane envelope (TM) protein gp41 
of HIV-1 failed so far. In contrast, in previous studies, immunising with the ectodomain of the TM protein p15E of 
different gammaretroviruses, we successfully induced neutralising antibodies. These antibodies recognised epitopes 
located in the fusion peptide proximal region (FPPR) and in the MPER of p15E. The epitope in the MPER of p15E 
corresponds to that of the mAb 4E10 in gp41 in terms of location within the protein and partial sequence homology. 
In order to present the MPER of gp41 (containing the 2F5 and 4E10 epitopes) membrane-associated, rats were 
immunised with DNA constructs corresponding (i) to the entire gp41, (ii) to the C-terminal helix of gp41 and (iii) to 
hybrid proteins composed of a backbone derived from p15E of a gammaretrovirus with inserted FPPR and MPER 
from gp41 of HIV-1. After transfection in vitro these proteins were found expressed at the cell surface and the 
accessibility of the 2F5 epitope was demonstrated by flow cytometry. However, DNA vaccination in rats resulted only 
in low titres of antibodies specific for the MPER of HIV-1, and none of the sera was neutralising. 
Figure 1: (a) Alignment of the amino acid sequences of the MPER of p15E 
of FeLV, PERV and KoRV and gp41 of HIV-1, identical amino acids are bold. 
(b) Schematic presentation of the antigens used in this study. Amino acid 
sequences derived from p15E of KoRV (DQ174772) are shown in white 
boxes and amino acid sequences derived from gp41 of HIV-1 (AF324493) are 
shown in grey boxes. Numbering below the drawings refers only to the amino 
acid sequence of gp41. The drawings are not in scale. FP–fusion peptide, 
FPPR–fusion peptide proximal region, MPER– membrane proximal external 
region, MSD–membrane spanning domain.
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lipids are required for the induction of such neutralising antibodies. 
One way to present the MPER of gp41 in a natural lipid environment 
is DNA vaccination allowing the MPER to be associated with the cell 
membrane. Although DNA vaccination was mainly used for induction 
of MHC-I specific cytotoxic cellular immune responses, it can also be 
used for the induction of humoral immune responses [27-30]. 
In this study, DNA constructs corresponding to the entire 
ectodomain of gp41, to the C-helical region of gp41 (gp41-CHR) as 
well as to hybrid constructs containing a gammaretrovirus backbone 
and sequences of the epitopes of mAb 2F5 and mAb 4E10 together with 
the FPPR were used in gene gun immunisation studies. Expression of 
gp41 and the hybrid antigens on the cell surface was demonstrated in 
vitro, and after immunisation of rats antibodies specific for gp41 were 
found. These findings may help to develop new strategies for a cell 
membrane-associated presentation of potential HIV vaccines in order 
to induce neutralising antibodies against conserved domains in gp41.
Materials and Methods 
Generation of the antigen-coding constructs 
The sequences of gp41-CHR and gp41 (Figure 1) were amplified by 
PCR (primers: CHR-for and CHR-rev; gp41-for and gp41-rev) (Table 
1) using the HIV-1 molecular clone pNL4-3 (AF324493) as a template. 
The hybrid sequences were generated by mutagenesis PCR using 
primers partly homologous to the KoRV-p15E sequence (DQ174772) 
and providing the HIV-1 gp41 specific sequences derived from pNL4-
3. The sequence of hybrid 1 (Hyb1) was generated by three sequentially 
performed PCRs using (i) primers T7-prom and MSD-1-rev on the 
template of pCal-n-KoRV-p15E [11], (ii) primers T7-prom and MSD-
2–rev on the template generated in step (i), (iii) primers T7-prom and 
MSD-3-rev on the template generated in step (ii). The sequence of Hyb2 
was generated using Hyb1 as template and performing mutagenesis 
PCR with the primers E1-for and MSD-3-rev. The hybrids Hyb3 to 
Hyb6 were generated similarly combining the reverse primer MSD-
3-rev with the desired forward primers Hyb3-for, Hyb4-for, Hyb5-for 
and Hyb6-for (Table 1 and Figure 1). All PCRs were performed under 
the following conditions: 95°C/10 min, 35 cycles: 95°C/45 s; 42°C/120 
s; 72°C/45 s, final extension: 72°C/10 min using the AmpliTaq Gold 
(Applied Biosystems, Foster City, USA). All PCR products were cloned 
into the eukaryotic surface expression vector pDisplay (Invitrogen, 
Karlsruhe, Germany) using the restriction sites BglII and PstI. The 
correctness of the reading frames were confirmed by sequencing. 
Plasmids were purified using the Endo-Free-Maxi Prep Kit (Qiagen, 
Hilden, Germany). 
Transfection of Rat-1 cells 
Lipofectamine 2000 reagent (Invitrogen, Karlsruhe, Germany) 
was used according to the manufactures instructions. 2×105/ml Rat-1 
cells were seeded into a 6-well cell culture plate and transfected with 
5 μg endotoxin-free plasmid when 80% cell confluence was reached. 
After 48 hours cells were transferred into DMEM containing 600 μg/ml 
geneticin (Invitrogen, Karlsruhe, Germany) in order to generate stably 
transfected cell lines. 
Flow cytometry 
Stably transfected Rat-1 cells were detached from the culture flask 
bottom using a cell scraper and washed three times with 10 ml of ice cold 
PBS. The cells were blocked for 30 min in ice cold PBS containing 10% 
(v/v) fetal bovine serum. mAb 2F5 (10 μg/ml) was added in blocking 
buffer. After incubation for 30 min on ice the cells were washed three 
times with ice cold PBS, and FITC-labelled secondary anti-human IgG 
antibodies (1:1000, Sigma, Munich, Germany) were added. Cells were 
incubated in the dark for 30 min on ice and then washed five times 
with PBS. Finally, 2% (v/v) formaldehyde (Roth, Karlsruhe, Germany) 
in PBS was added to fix the cells. Surface expression was assayed in a 
FACSCalibur cytometer (BD, Franklin Lakes, USA). Data were analysed 
using the CellQuest Pro software (BD, Franklin Lakes, USA).
DNA immunisation 
Endotoxin-free plasmids were precipitated onto gold particles 
(particle Ø 0.9 μm, 2.5 μg DNA/1mg gold). The coated particles were 
inoculated into the shaved abdominal skin of 4 weeks old Wistar 
rats (Charles River) using the Helios Gene Gun® (Bio Rad, Munich, 
Germany) with a helium impulse at 400 psi. Each rat received a triple 
application (1 μg/shot). Boost immunisations using the same procedure 
were performed on days 14 and 28 post primary immunisation. 
ELISA 
Peptide ELISAs were performed as described elsewhere 
[31]. 200 ng/well of the FPPR-derived peptide (aa524-547) 
(GAAGSTMGAASVTLTVQARLLLS) or the MPER-derived peptide 
(aa655-679) (NEQELLELDKWASLWNWFDITNWL) (JPT, Berlin, 
Germany) was coated on Nunc immunoplates (Nunc, Denmark) over 
night at 37°C. Sera were diluted 1:350 in blocking buffer. To detect 
antibodies specific for gp41 or KoRV p15E, purified recombinant gp41 
(aa530-683, reference K03455, 400 ng/well) and recombinant KoRV 
p15E (aa489-597, reference DQ174772, 200 ng/well) [11] were diluted 
in water and coated over night at 37°C.
Neutralisation assay 
A newly developed neutralisation assay based on the measurement 
of reduction of provirus integration as a marker for neutralisation 
was used [14,32]. Briefly: a 20 μl serum dilution and 80 μl HIV-
1IIIB (TCID50=10
3/ml) were incubated for 30 min at 37°C/5% CO2. 
C8166 cells (5×104 cells in 100 μl) were added and after 65 hours 
the supernatant was aspirated. Then cells were lysed and provirus 
integration was determined by an HIV-1 specific duplex real-time PCR 





















Table 1: Primers and probes used for the generation of constructs and for real 
time PCR.
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using the HIV-1 specific primers 68i and 69i [33] as well as an HIV-
1-probe (Table 1). To analyse toxic effects of the sera, simultaneously 
the amount of GAPDH genes (primers: hGAPDH-for and hGAPDH-
rev, probe: hGAPDH-probe, Table 1) was analysed. For amplification 
the real-time cycler MX-4000 (Stratagene, La Jolla, USA) was used 
with the following cycling conditions: 95°C/8 min+50 cycles: 95°C/45 
s– 55°C/60 s–72°C/20 s. Neutralisation (NT) was calculated using the 
formula: NT=100-100/2ΔΔCt. A reduction of 75% provirus integration 
(ΔCt=2) was defined as significant neutralisation. As positive control 
mAb 2F5 (5 μg/ml) was used.
Results 
DNA immunisation with gp41 and the CHR domain of gp41 
DNA constructs, corresponding to the entire gp41 and to the CHR 
domain of gp41 (gp41-CHR), were generated (Figure 1b). To study 
expression of the encoded proteins on the cell surface in vitro, stable 
transfected Rat-1 cells were analysed by flow cytometry using mAb 2F5 
(Figure 2). Fluorescence signals were detected with all transfected cell lines 
compared to untreated Rat-1 cells. Since the cells were not permeabilised, 
the observed staining indicated cell surface expression of all constructs as 
well as accessibility of the epitope of 2F5 when presented in such a way. Rats 
were immunised using these DNA constructs as described in Materials 
and methods. 14 days after the third immunisation, sera were taken and 
screened for binding antibodies in an ELISA. In nearly all sera (except 
serum from rat no. 6), gp41 specific antibodies were detected (Table 2). The 
highest titre (1:64,000) of gp41 specific binding antibodies was found in the 
sera from rats 9 to 12, immunised with a DNA construct corresponding 
to the entire gp41. Sera obtained by DNA immunisation with the gp41-
CHR construct showed a titre of gp41-binding antibodies of 1:8,000. When 
analysed for neutralising activity, none of the gp41 specific sera generated 
by DNA immunisation was able to neutralise HIV-1IIIB (Figure 3).
Design of DNA constructs corresponding to TM hybrid 
proteins 
Since DNA immunisation with the entire sequence of gp41 or the 
CHR of gp41 in a membrane-bound context did not induce neutralising 
antibodies, a new strategy for antigen design was developed. The 
sequence, corresponding to the epitopes of mAb 2F5 and mAb 4E10, 
and the sequence in the FPPR able to increase binding of mAb2F5 and 
mAb 4E10 to their epitopes [14] were inserted into the TM protein p15E 
of KoRV. p15E was used as a backbone and from this backbone the 
regions in the MPER and FPPR shown to contain epitopes recognised 
by antibodies neutralising KoRV were replaced by the gp41-specific 
MPER and FPPR domains (Figure 1b). We expected that the helical 
regions of p15E of KoRV will bring the MPER and FPPR derived from 
gp41 of HIV-1 in close proximity generating a conformation which 
allows inducing broadly neutralising antibodies. 
DNA immunisation with DNA constructs corresponding to 
TM hybrids 
To demonstrate the expression of the TM hybrid proteins, encoded 
Figure 2: Analysis of surface expression of gp41, gp41-CHR and 6 hybrid 
proteins after transfection of the corresponding DNA vaccines by flow 
cytometry (black-untreated Rat-1 cells, white-stable transfected Rat-1 cells, 
pDisplay-cells transfected with the empty vector). Antigens were detected 
using mAb 2F5 and stained with FITC-labeled anti-human-IgG.
















































































































































Table 2: ELISA analysis: gp41 specific binding antibodies (OD 492nm/620nm) 
induced by immunization with different antigens.
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by the DNA constructs described above, each of the six hybrid proteins 
(Hyb1-Hyb6) was transfected into Rat-1 cells and stable transfected 
lines were generated. Flow cytometry analysis of these cell lines using 
mAb 2F5 showed surface expression and accessibility of the 2F5 
epitope in all cases (Figure 2). All six DNA constructs were used for 
DNA immunisation, as described in Material and methods, and the 
induced sera were analysed in ELISAs. Only low titres of antibodies 
specific for synthetic peptides corresponding to the FPPR and MPER of 
gp41 were found (Table 2). As a rule, the responses against the FPPR-
derived peptide were stronger, compared with the responses against 
the MPER-derived peptide. To study the presence of neutralising 
antibodies in the immune sera, HIV-1IIIB was used in a real-time 
PCR-based neutralisation assay measuring provirus integration. This 
assay gave similar results when compared with the TZM-bl cell based 
assay and has numerous advantages [32]. Such neutralisation assays 
have been used to screen for neutralising antibodies specific for PERV 
[7], FeLV [8], KoRV [14] and HIV-2 [31]. None of the sera induced by 
DNA immunisation with the DNA hybrid constructs was able to reduce 
provirus integration of HIV-1IIIB (Figure 3).
Determination of antibodies directed against the p15E 
backbone 
Since the antibodies induced by DNA immunisation using the 
hybrid constructs Hyb1-Hyb6 were not neutralising HIV-1 (Figure 
3), the reactivity of the sera was analysed in more detail. To study 
the presence of antibodies specific for the p15E backbone, an ELISA 
using recombinant p15E of KoRV was performed. In all sera from rats 
immunised with DNA hybrid constructs antibodies against the p15E 
backbone were detected. This was rather astonishing, because after 
immunisation with p15E of different gammaretroviruses including 
KoRV, mainly antibodies against the FPPR and the MPER, but not 
against other parts of p15E were detected [6-10]. Surprisingly, sera 
from untreated control rats and from rats immunised with gp41 or 
gp41-CHR DNA constructs also contained antibodies against p15E 
of KoRV (Figure 4). These data indicate that in contrast to previous 
experiments antibodies against p15E of a gammaretrovirus were found 
in naïve Wistar rats not yet used for immunisation. The preformed 
antibodies against the p15E backbone may have interfered with the 
immune response against the hybrid protein containing FPPR-derived 
and MPER-derived from gp41 of HIV-1. This finding may partially 
explain the low titre of antibodies against the inserted HIV-1 sequences.
Discussion 
Immunisation of rats with DNA constructs corresponding to gp41, 
Figure 3: Results of the neutralisation assays using HIV-1IIIB and antisera 
induced in rats by DNA immunisation with different constructs as shown in 
Figure 1. MAb 2F5 was used as positive control. Each value is the result of a 
triplicate measurement. Significant neutralisation was defined as reduction of 
provirus integration above 75%.
to the C-terminal helix of gp41 (gp41-CHR) or to hybrid proteins 
composed of a backbone derived from p15E of the gammaretrovirus 
KoRV and the FPPR and MPER of gp41 of HIV-1 failed to induce 
neutralising antibodies. This new vaccination strategy was developed 
based on some recent findings: First, since immunising with p15E of 
different retroviruses was successful [6-11], hybrids were used because 
we expected that the helical regions of p15E bring the MPER and the 
FPPR of HIV-1, which substituted the FPPR and MPER of PERV, into 
close proximity, and the antigen may be able to induce neutralising 
antibodies. Second, a DNA immunisation approach was used to gain a 
membrane-associated localisation of the MPER expecting that it will be 
able to induce neutralising antibodies such as mAb 2F5. However, this 
approach failed despite the cell surface localisation of the expressed p41 
or gp41-CHR was shown. 
We recently identified a domain in the FPPR of gp41 that was 
able to enhance binding of mAb 2F5 and mAb 4E10 to their epitopes 
in the MPER [14]. Other authors had shown an interaction between 
MPER and FPPR during infection [18-22]. These findings suggested 
that the interaction between the MPER and the FPPR during infection 
may generate a conformation able to induce 2F5/4E10-like neutralising 
antibodies. However, all DNA constructs failed to induce antibodies 
significantly neutralising HIV-1 (Figure 3).
In other studies, the epitope sequence of 2F5 was added to the 
C-terminal part of p15E of PERV displayed on vesicular stomatitis virus 
particles in a membrane bound context [34] or as a rhinovirus hybrid 
[35] or in a pre-fusion state expressed on the surface of immature virus-
like particles from Sf9 cells [36]. Only low, if any, titres of neutralising 
antibodies were observed. Wang et al. [37] reported the induction of 
neutralising antibodies after immunisation with a protein containing 
the CHR, NHR and the MPER, which recognised an epitope in the 
MPER. Immunising guinea pigs with DNA or VLP based on a HA/gp41 
protein with a mutated Cys in the HA subunit, Ye et al. [38] reported 
a neutralising activity which could be blocked with a MPER-specific 
peptide, thus demonstrating induction of MPER-specific neutralising 
antibodies. Using a phage library, an HIV-1 elite controller was 
identified who developed antibodies against the MPER and neutralising 
antibodies were induced when immunising with the epitope phage 
[39]. Neutralising antibodies were also induced when using the epitope 
and synthetic sequential carriers or a palmitoyl group. On the other 
hand, immunising with VLP expressing the MPER Kandem Toukam et 
al. [40] were able to induce MPER-specific antibodies binding the 2F5 
epitope, but not neutralising. A conformation-specific display of 4E10 
and 2F5 epitopes on self-assembling protein nanoparticles also failed to 
induce neutralising antibodies [41].
There may be several reasons for the failure of many of the attempts 
to induce 2F5/4E10-like neutralising antibodies including our new 
approach: First, although it has been shown, that peptides derived from 
the FPPR increase the binding of mAb 2F5 to its epitope in the MPER/
E2 domain [14] and there is an interaction between MPER and FFPPR 
[18-22], it is still unknown whether this interaction is also required 
for the induction of 2F5/4E10-like broadly neutralising antibodies. 
Second, it remains unclear, whether the DNA immunisation generated 
the correct membrane associated context. HIV particles are budding 
from special regions of the cell membrane, so called rafts, that are 
characterised by specific lipid content [42] and it is unclear whether 
the DNA vaccines were also expressed in such a compartment. Third, 
conformational restrictions in the antigens expressed in vivo may have 
prevented the induction of neutralising antibodies. Fourth, pre-existing 
antibodies directed against the p15E backbone (Figure 4) may have 
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interfered with the antibody response against the gp41-derived FPPR 
and MPER when hybrids were used.
The finding that pre-formed antibodies against p15E exist in newly 
delivered rats is an interesting finding during these studies. It is likely 
that the antibodies reacting with p15E of the KoRV represent cross-
reacting antibodies specific for p15E of another related retrovirus 
probably an endogenous rat retrovirus. There are numerous data 
showing that endogenous retroviruses can be activated during mitogen 
stimulation of lymphocytes in vitro [43-45] and in immune responses 
in vivo [45,46]. Thus, further studies would be needed to investigate the 
origin of these pre-existing antibodies.
The present study using a new immunisation approach based 
on MPER-containing antigens underlines, that a much deeper 
understanding of the structure of gp41 and the interaction of FPPR and 
MPER is required to overcome the recent restrictions in the induction 
of 2F5/4E10-like antibodies.
Acknowledgment 
We would like to thank Annette Dietrich, Nicole Wagner and Kerstin Petsch 
for excellent technical assistance. The following reagents were obtained through 
the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, 
NIH: HTLV-IIIB/H9 from Dr. Robert Gallo, the monoclonal antibody 2F5 from Dr. 
Hermann Katinger and pNL4-3 from Dr. Malcolm Martin.
References
1. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, et al. (1993) A conserved 
neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 
67: 6642-6647. 
2. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, et al. (2001) 
Broadly neutralizing antibodies targeted to the membrane-proximal external 
region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75: 
10892-10905. 
3. Zwick MB (2005) The membrane-proximal external region of HIV-1 gp41: a 
vaccine target worth exploring. AIDS 19: 1725-1737. 
4. McGaughey GB, Barbato G, Bianchi E, Freidinger RM, Garsky VM, et al. 
(2004) Progress towards the development of a HIV-1 gp41-directed vaccine. 
Curr HIV Res 2: 193-204. 
5. Denner J (2011) Towards an AIDS vaccine: The transmembrane envelope 
protein as target for broadly neutralising antibodies. Hum Vaccin 7: 4-9. 
6. Fiebig U, Stephan O, Kurth R, Denner J (2003) Neutralizing antibodies against 
conserved domains of p15E of porcine endogenous retroviruses: basis for a 
vaccine for xenotransplantation? Virology 307: 406-413.
7. Kaulitz D, Fiebig U, Eschricht M, Wurzbacher C, Kurth R, et al. (2011) 
Generation of neutralising antibodies against porcine endogenous retroviruses 
(PERVs). Virology 411: 78-86. 
8. Langhammer S, Fiebig U, Kurth R, Denner J (2005) Neutralising antibodies 
against the transmembrane protein of feline leukaemia virus (FeLV). Vaccine 
23: 3341-3348. 
9. Langhammer S, Hübner J, Kurth R, Denner J (2006) Antibodies neutralizing 
feline leukaemia virus (FeLV) in cats immunized with the transmembrane 
envelope protein p15E. Immunology 117: 229-237. 
10. Langhammer S, Hübner J, Jarrett O, Kurth R, Denner J (2011) Immunization 
with the transmembrane protein of a retrovirus, feline leukemia virus: Absence 
of antigenemia following challenge. Antiviral Res 89: 119-123. 
11. Fiebig U, Hartmann MG, Bannert N, Kurth R, Denner J (2006) Transspecies 
transmission of the endogenous koala retrovirus. J Virol 80: 5651-5654. 
12. Sun ZY, Oh KJ, Kim M, Yu J, Brusic V, et al. (2008) HIV-1 broadly neutralizing 
antibody extracts its epitope from a kinked gp41 ectodomain region on the viral 
membrane. Immunity 28: 52-63. 
13. Alam SM, Scearce RM, Parks RJ, Plonk K, Plonk SG, et al. (2008) Human 
immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal 
region epitopes: antibody binding kinetics, induction, and potential for regulation 
in acute infection. J Virol 82: 115-125. 
14. Fiebig U, Eschricht M, Schmolke M, Kurth R, Denner J (2009) Mode of 
interaction between the HIV-1 neutralizing monoclonal antibody 2F5 and its 
epitope. AIDS 23: 887-895. 
15. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, et al. (2005) 
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 
antibodies. Science 308: 1906-1908. 
16. Alam SM, McAdams M, Boren D, Rak M, Scearce RM, et al. (2007) The role of 
antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-
HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 
membrane proximal envelope epitopes. J Immunol 178: 4424-4435. 
17. Matyas GR, Beck Z, Karasavvas N, Alving CR (2009) Lipid binding properties of 
4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim 
Biophys Acta 1788: 660-665. 
18. Lorizate M, de la Arada I, Huarte N, Sanchez-Martínez S, de la Torre BG, et 
al. (2006) Structural analysis and assembly of the HIV-1 Gp41 amino-terminal 
fusion peptide and the pretransmembrane amphipathic-at-interface sequence. 
Biochemistry 45: 14337-14346. 
19. Bellamy-McIntyre AK, Lay CS, Baär S, Maerz AL, Talbo GH, et al. (2007) 
Functional links between the fusion peptide-proximal polar segment and 
membrane-proximal region of human immunodeficiency virus gp41 in distinct 
phases of membrane fusion. J Biol Chem 282: 23104-23116. 
20. Noah E, Biron Z, Naider F, Arshava B, Anglister J (2008) The membrane 
proximal external region of the HIV-1 envelope glycoprotein gp41 contributes 
to the stabilization of the six-helix bundle formed with a matching N’ peptide. 
Biochemistry 47: 6782-6792. 
21. Buzon V, Natrajan G, Schibli D, Campelo F, Kozlov MM, et al. (2010) Crystal 
structure of HIV-1 gp41 including both fusion peptide and membrane proximal 
external regions. PLoS Pathog 6: e1000880.
22. Lay CS, Ludlow LE, Stapleton D, Bellamy-McIntyre AK, Ramsland PA, et al. 
(2011) Role for the terminal clasp of HIV-1 gp41 glycoprotein in the initiation of 
membrane fusion. J Biol Chem. 286: 41331-41343. 
23. Grundner C, Mirzabekov T, Sodroski J, Wyatt R (2002) Solid-phase 
proteoliposomes containing human immunodeficiency virus envelope 
glycoproteins. J Virol 76: 3511-3521. 
24. Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, et al. (2004) Structure and 
mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 
2F5 in complex with its gp41 epitope. J Virol 78: 10724-10737. 
25. Huarte N, Lorizate M, Maeso R, Kunert R, Arranz R, et al. (2008) The broadly 
neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal 
antibody is better adapted to membrane-bound epitope recognition and 
blocking than 2F5. J Virol 82: 8986-8996. 
26. Huarte N, Lorizate M, Kunert R, Nieva JL (2008) Lipid modulation of membrane- 
bound epitope recognition and blocking by HIV-1 neutralizing antibodies. FEBS 
Lett 582: 3798-3804. 
Figure 4: Demonstration of antibodies binding to KoRV p15E in immunised 
and non-immunised rats by ELISA using p15E of KoRV as antigen. Sera were 
tested at 1:500. As positive control a rat serum (R1) specific for p15E of KoRV 
was used.
Citation: Behrendt R, Fiebig U, Schmolke M, Kurth R, Denner J (2012) Induction of Antibodies Specific for Gp41 of HIV-1 by Gene Gun DNA 
Vaccination. J Vaccines Vaccin 3:145. doi:10.4172/2157-7560.1000145
Page 6 of 6
Volume 3 • Issue 4 • 1000145
J Vaccines Vaccin
ISSN:2157-7560 JVV an open access journal
27. Lu S, Santoro JC, Fuller DH, Haynes JR, Robinson HL (1995) Use of DNAs 
expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody 
responses in mice. Virology 209: 147-154. 
28. Vinne L, Nielsen HV, Bryder K, Corbet S, Nielsen C, et al. (1999) Gene gun 
DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene 
using mammalian codons. Vaccine 17: 2166-2175. 
29. Wild J, Bojak A, Deml L, Wagner R (2004) Influence of polypeptide size and 
intracellular sorting on the induction of epitope-specific CTL responses by DNA 
vaccines in a mouse model. Vaccine 22: 1732-1743. 
30. Wang S, Arthos J, Lawrence JM, Van Ryk D, Mboudjeka I, et al. (2005) 
Enhanced immunogenicity of gp120 protein when combined with recombinant 
DNA priming to generate antibodies that neutralize the JR-FL primary isolate of 
human immunodeficiency virus type 1. J Virol 79: 7933-7937. 
31. Tacke SJ, Bodusch K, Berg A, Denner J (2001) Sensitive and specific 
immunological detection methods for porcine endogenous retroviruses 
applicable to experimental and clinical xenotransplantation. Xenotransplantation 
8: 125-135. 
32. Behrendt R, Fiebig U, Norley S, Gürtler L, Kurth R, et al. (2009) A neutralization 
assay for HIV-2 based on measurement of provirus integration by duplex real-
time PCR. J Virol Methods 159: 40-46. 
33. Cassol S, Rudnik J, Salas T, Montpetit M, Pon RT, et al. (1992) Rapid DNA 
fingerprinting to control for specimen errors in HIV testing by the polymerase 
chain reaction. Mol Cell Probes 6: 327-331. 
34. Luo M, Yuan F, Liu Y, Jiang S, Song X, et al. (2006) Induction of neutralizing 
antibody against human immunodeficiency virus type 1 (HIV-1) by immunization 
with gp41 membrane-proximal external region (MPER) fused with porcine 
endogenous retrovirus (PERV) p15E fragment. Vaccine 24: 435-442. 
35. Arnold GF, Velasco PK, Holmes AK, Wrin T, Geisler SC, et al. (2009) Broad 
neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from 
human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol 83: 
5087-5100. 
36. Kim M, Qiao Z, Yu J, Montefiori D, Reinherz EL (2007) Immunogenicity of 
recombinant human immunodeficiency virus type 1-like particles expressing 
gp41 derivatives in a pre-fusion state. Vaccine 2007 25: 5102-5114.
37. Wang J, Tong P, Lu L, Zhou L, Xu L, et al. (2011) HIV-1 gp41 core with 
exposed membrane-proximal external region inducing broad HIV-1 neutralizing 
antibodies. PLoS One. 6: e18233. 
38. Ye L, Wen Z, Dong K, Wang X, Bu Z, et al. (2011) Induction of HIV neutralizing 
antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric 
protein-based DNA and VLP vaccines. PLoS One 6: e14813.
39. Zhou M, Kostoula I, Brill B, Panou E, Sakarellos-Daitsiotis M, et al. (2012) 
Prime boost vaccination approaches with different conjugates of a new HIV-1 
gp41 epitope encompassing the membrane proximal external region induce 
neutralizing antibodies in mice. Vaccine 30: 1911-1916. 
40. Kamdem Toukam D, Tenbusch M, Stang A, Temchura V, Storcksdieck M, et 
al. (2012) Targeting antibody responses to the membrane proximal external 
region of the envelope glycoprotein of human immunodeficiency virus. PLoS 
One 7: e38068. 
41. Wahome N, Pfeiffer T, Ambiel I, Yang Y, Keppler OT, et al. (2012) Conformation-
specific display of 4E10 and 2F5 epitopes on self-assembling protein 
nanoparticles as a potential HIV vaccine. Chem Biol Drug Des 80: 349-357.
42. Alving CR, Beck Z, Karasavva N, Matyas GR, Rao M (2006) HIV-1, lipid rafts, 
and antibodies to liposomes: implications for anti-viral-neutralizing antibodies. 
Mol Membr Biol 23: 453-465. 
43. Stoye JP, Moroni C (1983) Endogenous retrovirus expression in stimulated 
murine lymphocytes. Identification of a new locus controlling mitogen induction 
of a defective virus. J Exp Med 157: 1660-1674. 
44. Tacke SJ, Specke V, Denner J (2003) Differences in release and determination 
of subtype of porcine endogenous retroviruses (PERV) produced by stimulated 
normal pig blood cells. Intervirology 46: 17-24. 
45. Hirsch MS, Phillips SM, Solnik C, Black PH, Schwartz RS (1972) Activation of 
leukemia viruses by graft-versus-host and mixed lymphocyte reactions in vitro. 
Proc Natl Acad Sci U S A 69: 1069-1072. 
46. Denner J, Dorfman N (1977) Small virus-like particles in leukosis-like syndrome 
induced by certain antigens and immunostimulators. Acta Biol Med Ger 36: 
1451-1458.
Submit your next manuscript and get advantages of OMICS 
Group submissions
Unique features:
•	 User	friendly/feasible	website-translation	of	your	paper	to	50	world’s	leading	languages
•	 Audio	Version	of	published	paper
•	 Digital	articles	to	share	and	explore
Special features:
•	 200	Open	Access	Journals
•	 15,000	editorial	team
•	 21	days	rapid	review	process
•	 Quality	and	quick	editorial,	review	and	publication	processing
•	 Indexing	at	PubMed	(partial),	Scopus,	DOAJ,	EBSCO,	Index	Copernicus	and	Google	Scholar	etc
•	 Sharing	Option:	Social	Networking	Enabled
•	 Authors,	Reviewers	and	Editors	rewarded	with	online	Scientific	Credits
•	 Better	discount	for	your	subsequent	articles
Submit	your	manuscript	at:	www.editorialmanager.com/pharma
